Harsha Rajasimha

Harsha Rajasimha, MS, Ph.D.
Harsha is a serial entrepreneur, postdoctoral data scientist trained at NIH, global patient advocate, and investor. As the founder and CEO of Jeeva Clinical Trials Inc.(https://jeevatrials.com), Harsha is pioneering an AI-driven unified platform for sponsors and CROs to execute patient-centric clinical trials with efficiency and universal accessibility. As the Founder & executive chair of the Indo-US Organization for Rare Diseases (https://indousrare.org), Harsha is forging a new era of cross-border cooperation among various stakeholders of rare diseases in the US, India, and globally by convening the annual Indo US bridging RARE Summit (https://summit.indousrare.org) and the Abbey Meyers Khushi Bridging RARE Awards Gala.
Harsha’s 20 years of experience in precision medicine data research spans academia, federally funded research, biopharma R&D consulting, and multiple startups. Harsha made bold career moves after losing a newborn child to a rare congenital disease in 2012 and his younger brother with juvenile diabetes in 2017. He decided to apply his years of postdoctoral training at NIH and FDA to combat rare diseases.
Harsha has maintained academic affiliation at George Mason University since 2012 and has authored 20+ publications, book chapters, and patents. Harsha’s work has been recognized by RDDC Caregiver RISE Award 2025, Nominated for the RareVoice Award 2024, Lead India Foundation 2020, a travel award to join the NGO Committee on Rare Diseases at the United Nations headquarters, New York City in Feb 2019, NTT DATA Healthcare Life Sciences Silver award for outstanding achievement 2017, Sanofi Genzyme patient advocacy leadership award 2016. Harsha earned his M.S. in Computer Science (2004) and Ph.D. in Genetics, Bioinformatics and Computational Biology (2007) from Virginia Tech.